This research evaluates how the initial site of metastasis affects survival in pancreatic ductal adenocarcinoma.
Compared survival outcomes between patients with lung and liver metastases at initial presentation.
Analyzed data on metastatic sites and survival rates in a cohort of patients with mPDAC.
Patients with initial lung metastases had better survival outcomes than those with initial liver metastases.
The survival difference suggests that the metastatic site is a significant prognostic factor for mPDAC.
Abstract
Initial presentation with lung metastases appears to be associated with improved survival outcomes as compared to initial presentation with liver metastases in patients with mPDAC.